FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2039596286> ?p ?o ?g. }

• W2039596286 endingPage "627" @default.
• W2039596286 startingPage "624" @default.
• W2039596286 abstract "No AccessJournal of UrologyClinical Urology: Original Article1 Feb 19965-Fluorouracil and Allopurinol Combined with Recombinant Interferon-alpha 2b in the Treatment of Patients with Advanced Prostate Cancer: A Phase I/II Study David B. Glazier, John A. Heaney, Robert J. Amdur, Alan R. Schned, Robert Harris, Iwao Fukui, and Marc S. Ernstoff David B. GlazierDavid B. Glazier More articles by this author , John A. HeaneyJohn A. Heaney More articles by this author , Robert J. AmdurRobert J. Amdur More articles by this author , Alan R. SchnedAlan R. Schned More articles by this author , Robert HarrisRobert Harris More articles by this author , Iwao FukuiIwao Fukui More articles by this author , and Marc S. ErnstoffMarc S. Ernstoff More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)66469-3AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We determined the toxicity and preliminary response rate of escalating doses of 5-fluorouracil (670 to 1,500 mg./m.2 per day) combined with a fixed dose of interferon-alpha 2b (5 million units) and allopurinol (300 mg. every 8 hours) in cohorts of patients with metastatic prostate cancer. Materials and Methods: The trial included 11 men with metastatic prostate cancer. Cohorts of patients received a 5-day constant infusion of 5-fluorouracil combined with subcutaneous interferon-alpha 2b 3 times weekly and allopurinol for 1 week during 5-fluorouracil infusion. Treatment was repeat every 3 weeks. Results: Of 10 patients evaluable for treatment response and toxicity 3 had a partial response as judged by significant decreases in prostate specific antigen measurements (mean followup 13.5 months). Significant dose limiting toxicities encountered included mucositis, diarrhea and leukoneutropenia. Conclusions: Further evaluation of this treatment to determine overall response rates and benefit should take into consideration the significant toxicity experienced. References 1 : Cancer statistics, 1995. CA1995; 45: 8. Google Scholar 2 : Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Seminol. Oncol.1988; 15: 371. Google Scholar 3 : Prostate cancer. Chemotherapy. Cancer1987; 60: 586. Google Scholar 4 : The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate. J. Urol.1976; 116: 211. Link, Google Scholar 5 : The chemotherapy of urologic cancer. Cancer1975; 36: 729. Google Scholar 6 : Fluorouracil and recombinant alpha-2a-interferon: an active regimen against advanced colorectal carcinoma. J. Clin. Oncol.1989; 7: 1769. Google Scholar 7 : Pre clinical and clinical studies of 5-fluorouracil and recombinant alpha-2a-interferon against gastrointestinal malignancies. Clin. Res.1988; 36: 803A. Google Scholar 8 : Therapy with 5-fluorouracil and recombinant alpha 2a interferon in refractory gastrointestinal malignancies. Proc. Amer. Soc. Clin. Oncol.1989; 8: 99. Google Scholar 9 : Allopurinol modulation of fluorouracil toxicity. Cancer Chemother. Pharmacol.1981; 5: 151. Google Scholar 10 : Allopurinol modulation of high-dose fluorouracil toxicity. Lancet1979; 1: 677. Google Scholar 11 : Modulation of 5-fluorouracil toxicity by allopurinol in man. Cancer1981; 48: 1281. Google Scholar 12 : 5-FU and allopurinol: toxicity modulation and phase II results in colon cancer. Cancer Treat. Rep.1982; 66: 1133. Google Scholar 13 : Mechanisms of interaction of interferon and 5-fluorouracil in solid tumors. Sem. Oncol.1991; 18: 77. Google Scholar 14 : Design and analysis of phase I clinical trials. Biometrics1989; 45: 925. Google Scholar 15 : Total prostatectomy for clinically localized prostatic cancer: long-term results. J. Urol.1989; 141: 564. Link, Google Scholar 16 : Phase II trial of 5-fluorouracil and alpha-2b interferon in patients with hormone-refractory metastatic prostate cancer. Urology1994; 44: 377. Google Scholar 17 : Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res.1994; 54: 1760. Google Scholar 18 : Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation. Urol. Clin. N. Amer.1991; 18: 123. Google Scholar Departments of Urology and Pathology and Sections of Radiology and Hematology/Oncology, Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center, Lebanon, New Hampshire, and Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan.© 1996 by American Urological Association, Inc.FiguresReferencesRelatedDetails Volume 155Issue 2February 1996Page: 624-627 Advertisement Copyright & Permissions© 1996 by American Urological Association, Inc.MetricsAuthor Information David B. Glazier More articles by this author John A. Heaney More articles by this author Robert J. Amdur More articles by this author Alan R. Schned More articles by this author Robert Harris More articles by this author Iwao Fukui More articles by this author Marc S. Ernstoff More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2039596286 created "2016-06-24" @default.
• W2039596286 creator A5029533287 @default.
• W2039596286 creator A5031516173 @default.
• W2039596286 creator A5068270443 @default.
• W2039596286 creator A5080259332 @default.
• W2039596286 creator A5083258118 @default.
• W2039596286 creator A5089516753 @default.
• W2039596286 creator A5089576509 @default.
• W2039596286 date "1996-02-01" @default.
• W2039596286 modified "2023-09-27" @default.
• W2039596286 title "5-Fluorouracil and Allopurinol Combined with Recombinant Interferon-alpha 2b in the Treatment of Patients with Advanced Prostate Cancer: A Phase I/II Study" @default.
• W2039596286 cites W1964487497 @default.
• W2039596286 cites W1964823588 @default.
• W2039596286 cites W1973949121 @default.
• W2039596286 cites W1979903252 @default.
• W2039596286 cites W2037449699 @default.
• W2039596286 cites W2054383376 @default.
• W2039596286 cites W2155249414 @default.
• W2039596286 cites W2269247374 @default.
• W2039596286 cites W2406607853 @default.
• W2039596286 cites W2469820878 @default.
• W2039596286 cites W2470050007 @default.
• W2039596286 doi "https://doi.org/10.1016/s0022-5347(01)66469-3" @default.
• W2039596286 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8558676" @default.
• W2039596286 hasPublicationYear "1996" @default.
• W2039596286 type Work @default.
• W2039596286 sameAs 2039596286 @default.
• W2039596286 citedByCount "7" @default.
• W2039596286 crossrefType "journal-article" @default.
• W2039596286 hasAuthorship W2039596286A5029533287 @default.
• W2039596286 hasAuthorship W2039596286A5031516173 @default.
• W2039596286 hasAuthorship W2039596286A5068270443 @default.
• W2039596286 hasAuthorship W2039596286A5080259332 @default.
• W2039596286 hasAuthorship W2039596286A5083258118 @default.
• W2039596286 hasAuthorship W2039596286A5089516753 @default.
• W2039596286 hasAuthorship W2039596286A5089576509 @default.
• W2039596286 hasConcept C121608353 @default.
• W2039596286 hasConcept C126322002 @default.
• W2039596286 hasConcept C126894567 @default.
• W2039596286 hasConcept C141071460 @default.
• W2039596286 hasConcept C143998085 @default.
• W2039596286 hasConcept C203014093 @default.
• W2039596286 hasConcept C2776178377 @default.
• W2039596286 hasConcept C2780192828 @default.
• W2039596286 hasConcept C2780261098 @default.
• W2039596286 hasConcept C2780456651 @default.
• W2039596286 hasConcept C2781228144 @default.
• W2039596286 hasConcept C2909179924 @default.
• W2039596286 hasConcept C29730261 @default.
• W2039596286 hasConcept C71924100 @default.
• W2039596286 hasConcept C90924648 @default.
• W2039596286 hasConceptScore W2039596286C121608353 @default.
• W2039596286 hasConceptScore W2039596286C126322002 @default.
• W2039596286 hasConceptScore W2039596286C126894567 @default.
• W2039596286 hasConceptScore W2039596286C141071460 @default.
• W2039596286 hasConceptScore W2039596286C143998085 @default.
• W2039596286 hasConceptScore W2039596286C203014093 @default.
• W2039596286 hasConceptScore W2039596286C2776178377 @default.
• W2039596286 hasConceptScore W2039596286C2780192828 @default.
• W2039596286 hasConceptScore W2039596286C2780261098 @default.
• W2039596286 hasConceptScore W2039596286C2780456651 @default.
• W2039596286 hasConceptScore W2039596286C2781228144 @default.
• W2039596286 hasConceptScore W2039596286C2909179924 @default.
• W2039596286 hasConceptScore W2039596286C29730261 @default.
• W2039596286 hasConceptScore W2039596286C71924100 @default.
• W2039596286 hasConceptScore W2039596286C90924648 @default.
• W2039596286 hasIssue "2" @default.
• W2039596286 hasLocation W20395962861 @default.
• W2039596286 hasLocation W20395962862 @default.
• W2039596286 hasOpenAccess W2039596286 @default.
• W2039596286 hasPrimaryLocation W20395962861 @default.
• W2039596286 hasRelatedWork W1983114720 @default.
• W2039596286 hasRelatedWork W1985882441 @default.
• W2039596286 hasRelatedWork W1991827935 @default.
• W2039596286 hasRelatedWork W2064724738 @default.
• W2039596286 hasRelatedWork W2227455752 @default.
• W2039596286 hasRelatedWork W2275704229 @default.
• W2039596286 hasRelatedWork W2321925860 @default.
• W2039596286 hasRelatedWork W2387826253 @default.
• W2039596286 hasRelatedWork W2429782989 @default.
• W2039596286 hasRelatedWork W1625444068 @default.
• W2039596286 hasVolume "155" @default.
• W2039596286 isParatext "false" @default.
• W2039596286 isRetracted "false" @default.
• W2039596286 magId "2039596286" @default.
• W2039596286 workType "article" @default.